A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer by Khrystany T. Isebia, Martijn P. Lolkema, Guido Jenster, Ronald de Wit, John W. M. Martens, Job van Riet

Get full text

Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model by Lisanne Mout, Ronald de Wit, Debra Stuurman, Esther Verhoef, Ron Mathijssen, Corrina de Ridder, Martijn Lolkema, Wytske van Weerden

Get full text

Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning by Anouk C. de Jong, Alexandra Danyi, Job van Riet, Ronald de Wit, Martin Sjöström, Felix Feng, Jeroen de Ridder, Martijn P. Lolkema

Get full text

Neutropenia, neutrophilia, and neutrophil–lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer by Alexander Meisel, Ronald de Wit, Stephane Oudard, Oliver Sartor, Frank Stenner-Liewen, Zhenming Shun, Meredith Foster, Ayse Ozatilgan, Mario Eisenberger, Johann S. de Bono

Get full text

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RAN... by Andrea Necchi, Hiroyuki Nishiyama, Nobuaki Matsubara, Jae-Lyun Lee, Daniel P. Petrylak, Ronald de Wit, Alexandra Drakaki, Astra M. Liepa, Huzhang Mao, Katherine Bell-McGuinn, Thomas Powles

Get full text

11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration by Gido Snaterse, Lisanne F. van Dessel, Job van Riet, Angela E. Taylor, Michelle van der Vlugt-Daane, Paul Hamberg, Ronald de Wit, Jenny A. Visser, Wiebke Arlt, Martijn P. Lolkema, Johannes Hofland

Get full text

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study by Andrea Necchi, Michiel S. Van der Heijden, Dmytro Trukhin, Avivit Peer, Howard Gurney, Boris Y. Alekseev, Francis X. Parnis, Raya Leibowitz, Maria De Santis, Petros Grivas, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Arjun V. Balar, Ronald de Wit

Get full text

mFast‐SeqS‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer by Khrystany T. Isebia, Bianca Mostert, Teoman Deger, Jaco Kraan, Vanja deWeerd, Esther Oomen‐de Hoop, Paul Hamberg, Brigitte C. M. Haberkorn, Helgi H. Helgason, Ronald deWit, Ron H. J. Mathijssen, Martijn P. Lolkema, Saskia M. Wilting, Job vanRiet, John W. M. Martens

Get full text

A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide by Stefan A.J. Buck, Marinda Meertens, Frederiek M.F. van Ooijen, Esther Oomen-de Hoop, Evert de Jonge, Marieke J.H. Coenen, Andries M. Bergman, Stijn L.W. Koolen, Ronald de Wit, Alwin D.R. Huitema, Ron H.N. van Schaik, Ron H.J. Mathijssen

Get full text

Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer by Pauline A. J. Mendelaar, Debbie G. J. Robbrecht, Maud Rijnders, Ronald deWit, Vanja deWeerd, Teoman Deger, Hans M. Westgeest, Maureen J. B. Aarts, Jens Voortman, John W. M. Martens, Astrid A. M. van derVeldt, José Alberto Nakauma‐González, Saskia M. Wilting, Martijn Lolkema

Get full text

Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study by Berbel L. M. Ykema, Tanya M. Bisseling, Manon C. W. Spaander, Leon M. G. Moons, Dorien van der Biessen-van Beek, Lisette Saveur, Martijn Kerst, Sasja F. Mulder, Ronald de Wit, Danielle Zweers, Gerrit A. Meijer, Jos H. Beijnen, Iris Lansdorp-Vogelaar, Flora E. van Leeuwen, Petur Snaebjornsson, Monique E. van Leerdam

Get full text

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel by Anieta M. Sieuwerts, Wendy Onstenk, Jaco Kraan, Corine M. Beaufort, Mai Van, Bram De Laere, Luc Y. Dirix, Paul Hamberg, Aart Beeker, Hielke J. Meulenbeld, Geert‐Jan Creemers, Wytske M. vanWeerden, Guido W. Jenster, Annemieke J. M. Nieuweboer, Ron H. J. Mathijssen, Ronald deWit, John W. M. Martens, Stefan Sleijfer

Get full text

Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer by Maud Rijnders, J. Alberto Nakauma-González, Debbie G. J. Robbrecht, Alberto Gil-Jimenez, Hayri E. Balcioglu, Astrid A. M. Oostvogels, Maureen J. B. Aarts, Joost L. Boormans, Paul Hamberg, Michiel S. van der Heijden, Bernadett E. Szabados, Geert J. L. H. van Leenders, Niven Mehra, Jens Voortman, Hans M. Westgeest, Ronald de Wit, Astrid A. M. van der Veldt, Reno Debets, Martijn P. Lolkema

Get full text

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact by Lisanne F. van Dessel, Job van Riet, Minke Smits, Yanyun Zhu, Paul Hamberg, Michiel S. van der Heijden, Andries M. Bergman, Inge M. van Oort, Ronald de Wit, Emile E. Voest, Neeltje Steeghs, Takafumi N. Yamaguchi, Julie Livingstone, Paul C. Boutros, John W. M. Martens, Stefan Sleijfer, Edwin Cuppen, Wilbert Zwart, Harmen J. G. van de Werken, Niven Mehra, Martijn P. Lolkema

Get full text

International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer by Marieke van Leeuwen, Jacobien M. Kieffer, Fabio Efficace, Sophie D. Fosså, Michel Bolla, Laurence Collette, Marc Colombel, Ugo De Giorgi, Bernhard Holzner, Lonneke V. van de Poll-Franse, Hendrik van Poppel, Jeff White, Ronald de Wit, Susanne Osanto, Neil K. Aaronson, for the European Organisation for Research and Treatment of Cancer Quality of Life Group, Genito-Urinary Cancers Group and Radiation Oncology Group, and the NCRN Testis Clinical Studies Group

Get full text

Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial by Michiel S. van der Heijden, Thomas Powles, Daniel Petrylak, Ronald de Wit, Andrea Necchi, Cora N. Sternberg, Nobuaki Matsubara, Hiroyuki Nishiyama, Daniel Castellano, Syed A. Hussain, Aristotelis Bamias, Georgios Gakis, Jae-Lyun Lee, Scott T. Tagawa, Ulka Vaishampayan, Jeanny B. Aragon-Ching, Bernie J. Eigl, Rebecca R. Hozak, Erik R. Rasmussen, Meng Summer Xia, Ryan Rhodes, Sameera Wijayawardana, Katherine M. Bell-McGuinn, Amit Aggarwal, Alexandra Drakaki

Get full text